. Author manuscript; available in PMC: 2014 Dec 1.

Published in final edited form as: J Health Econ. 2013 May 6;32(6):10.1016/j.jhealeco.2013.04.007. doi: 10.1016/j.jhealeco.2013.04.007

Table 7.

Adjusted Difference-in-difference in MPR, GDR, and Number of Scripts by Drug for Employer-provided Sample

		MPR		GDR

	Number of Observations+	Non-LIS, Gap coverage vs. Employer- Provided	Non-LIS, No gap coverage vs. Employer-provided	Non-LIS, Gap coverage vs. Employer-provided	Non-LIS, No gap coverage vs. Employer-provided
All Classes		−0.031 ^***	−0.035 ^***	0.038 ^***	0.028 ^***
Statins	314,212	−0.048 ^***	−0.048 ^***	0.035 ^***	0.018 ^***
Anti-hypertensives, combo	88,904	−0.039 ^***	−0.040 ^***	0.043 ^***	0.01
Oral hypoglycemics	254,462	−0.033 ^***	−0.035 ^***	0.045 ^***	0.027 ^***
Calcium channel blockers	140,588	−0.003	−0.015 ^***	−0.019 ^*	−0.019 ^**
Anti-hypertensives, other	26,514	−0.006	−0.013	N/A	N/A
ACE/ARB	237,134	−0.057 ^***	−0.059 ^***	0.012	0.003
Beta blockers	188,080	−0.013 ^**	−0.019 ^***	0.095 ^***	0.095 ^***
Diuretics	127,760	0.005	−0.006	N/A	N/A
Digitalis glycosides	39,466	−0.010	−0.012	−0.04 ^**	−0.04 ^**

NOTE: Sample is individuals with diabetes and ages 65 and older that reach coverage gap in 2007. Differences are in percentage points. GDR for ACE/ARB class is for ACE Inhibitors only since ARB class is brand-dominated. Results are from regression models. Model includes age, sex, race, and indicators for ending in catastrophic phase, age-squared, co-morbid conditions, and plan type. + Number of observations for MPR calculations. Significance levels are indicated as the following

p<.050

^**

p<.010

^***

P<.001. Average cost is empirically derived, for 30-day equivalent. Year: 2007